Capital Operations - The company plans to raise no more than 1.253 billion yuan through a new round of private placement, with 883 million yuan allocated for innovative drug development and 370 million yuan for working capital [2] - This marks the largest private placement since the company went public, and the approval results may significantly impact the company's funding chain for research and development [2] Performance Overview - The company expects a net loss attributable to shareholders of between 85.33 million yuan and 69.81 million yuan for 2025, primarily due to a decline in revenue from its core product, Shutaqing, despite a slight increase in sales of Sutai Sheng [3] - The official annual report is expected to be disclosed before April 2026, with a focus on the actual loss magnitude and cash flow improvement [3] Shareholder Actions - Major shareholder Xiangtang Group reduced its holdings from November to December 2025, dropping below 5% on December 26, 2025, raising concerns about potential impacts on stock price stability and corporate governance confidence [4] Product Development Progress - The key project, STSP-0601, has received priority review status from the National Medical Products Administration and orphan drug designation from the FDA, with future approval progress being closely monitored [5] - Other projects, including STSA-1002 and BDB-001, are in clinical trial stages, and the disclosure of clinical data in 2026 may act as a catalyst for stock price [5] Industry Policies and Environment - The company's first generic drug, Shuchangqing, was suspended from procurement in September 2025, directly affecting new drug market promotion [6] - Core products, Sutai Sheng and Shutaqing, contribute over 90% of revenue but are experiencing continuous revenue contraction due to centralized procurement and medical insurance policies, necessitating attention to the effectiveness of marketing strategy adjustments in 2026 [6] Financial Condition - The company has reported negative operating cash flow for six consecutive years, with a net outflow of 107 million yuan in the first three quarters of 2025 [7] - Coupled with uncertainties surrounding the private placement, the tightening of the funding chain may worsen, requiring monitoring of debt levels and financing progress [7]